+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030

  • PDF Icon

    Report

  • 310 Pages
  • November 2019
  • Region: Global
  • Roots Analysis
  • ID: 4988877
Description Jump to:

Overview

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 200 in the pipeline (clinical/preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells/pathogens, consequently, addressing most of the concerns related to off target toxicities. In this context, the role of the linker molecule and the conjugation technology used is pivotal. In fact, conjugation chemistry has been shown to be directly related to the drug to antibody ratio (DAR) achieved, and thereby, governs the pharmacokinetic and pharmacodynamic properties of an ADC. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. Over time, the evolution of recombinant DNA technology and advances in conjugation techniques, have enabled researchers to significantly improve the bioconjugation process. In fact, next-generation conjugation technologies use artificially integrated lysine/cysteine residues in order to improve the DAR of the resulting conjugate. Additionally, there are multiple technologies that claim to offer site-specific conjugation. There are a number of other noteworthy developments in the conjugation technologies domain, which include a variety of competent platforms based on various ligation, disulfide rebridging and protein remodeling approaches. Further, linker technologies have also evolved substantially, and there is vast array of linkers, including cleavable and non-cleavable variants, which are designed to govern drug release mechanism of conjugated therapeutic molecules.

It is worth highlighting that multiple licensing agreements/collaborations have been inked between drug developers and technology providers to advance the development of pipeline ADC candidates. Over the years, a number of start-ups/small companies, offering novel conjugation technologies, more potent cytotoxins/warheads and advanced linker chemistries, have been established to facilitate development of ADCs and other conjugated pharmaceuticals. We anticipate this niche and upcoming market to witness substantial growth over the coming years.

Scope of the Report

The “Antibody Drug Conjugates: Linker and Conjugation Technologies Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities within the ADC linker and conjugation technologies market, over the next 10-12 years. In addition to other elements, the report includes:


  • An overview of the overall landscape of ADC linker and conjugation technologies, featuring  an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.
  • Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.
  • A list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company’s ADC pipeline strength, likely partners and development status of the ADC molecules.
  • A detailed competitiveness analysis of ADC linker and conjugation technologies, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as ADC generation, type of linker, DAR of the ADCs developed using the technology, availability of patent protection, number of deals signed for a particular technology (2016-2019),  and popularity of the technology (in terms of the number of ADCs developed using the technology).
  • An in-depth analysis of the various patents that have been filed/granted related to linker/conjugation technologies till August 2019, taking into consideration parameters, such as patent type, publication year, issuing authority/patent offices involved, CPC symbol, emerging focus areas and leading industry/academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for ADC linker and conjugation technologies. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across the [A] type of linker (cleavable, non-cleavable and both), [B] type of conjugation (chemical, enzymatic and others) [C] key technologies, and [D] key geographical regions (North America, Europe and Asia Pacific/ rest of the world). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following industry stakeholders:


  • Mary Chaohong Hu (Chief Executive Officer, Shanghai Miracogen)
  • Wouter Verhoeven (Chief Business Officer, NBE Therapeutics)
  • Floris van Delft (Chief Scientific Officer, Synaffix)
  • Jan Modregger (Head of Research & Development, EUCODIS Bioscience)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibody-based Therapeutics
3.3 Antibody Drug Conjugates (ADCs)
3.3.1 Components of ADCs
3.3.1.1 Antibody
3.3.1.2 Cytotoxin
3.3.1.3 Linker
3.4. Advantages of ADCs over Traditional Pharmacological Interventions
3.5. ADC Linker Technologies
3.5.1. Non-cleavable Linkers
3.5.2. Cleavable Linkers
3.6. ADC Conjugation Technologies
3.6.1. Chemical Conjugation
3.6.2. Enzymatic Conjugation
3.7. Future Perspectives
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by ADC Generation
4.2.3. Analysis by Type of Linker
4.2.4. Analysis by Type of Conjugation
4.2.5. Analysis by Site Specificity
4.2.6. Analysis by Drug to Antibody Ratio
4.2.7. Analysis by Patent Availability
4.2.8. Analysis by Licensing Activity
4.3. ADC Linker and Conjugation Technologies: Developer Landscape
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Geographical Location
4.3.4 Leading ADC Developers: Analysis by Number of Technologies
4.3.5 Grid Representation: Analysis by ADC Generation, Type of Linker, Company Size, and Geographical Location
4.3.6 World Map Representation: Analysis by Geography
4.4 ADC Linker and Conjugation Technologies: Service Providers
5. COMPANY PROFILES
5.1 Chapter Overview
5.2 Key Players in North America
5.2.1 Ambrx
5.2.1.1 Company Overview
5.2.1.2 Technology Overview
5.2.1.3 Recent Developments and Future outlook
5.2.2 Catalent Biologics
5.2.2.1 Company Overview
5.2.2.2 Financial Information
5.2.2.3 Technology Overview
5.2.2.4 Recent Developments and Future outlook
5.2.3 Immunomedics
5.2.3.1 Company Overview
5.2.3.2 Financial Information
5.2.3.3 Technology Overview
5.2.3.4 Recent Developments and Future outlook
5.2.4 Mersana Therapeutics
5.2.4.1 Company Overview
5.2.4.2 Financial Information
5.2.4.3 Technology Overview
5.2.4.4 Recent Developments and Future outlook
5.2.5 Seattle Genetics
5.2.5.1 Company Overview
5.2.5.2 Financial Information
5.2.5.3 Technology Overview
5.2.5.4 Recent Developments and Future outlook
5.2.6 Sutro Biopharma
5.2.6.1 Company Overview
5.2.6.2 Financial Information
5.2.6.3 Technology Overview
5.2.6.4 Recent Developments and Future outlook
5.3 Key Players in Europe and Asia
5.3.1 Iksuda Therapeutics
5.3.1.1 Company Overview
5.3.1.2 Technology Overview
5.3.1.3 Recent Developments and Future outlook
5.3.2 LegoChem Biosciences
5.3.2.1 Company Overview
5.3.2.2 Technology Overview
5.3.2.3 Recent Developments and Future outlook
5.3.3 LinXis
5.3.3.1 Company Overview
5.3.3.2 Technology Overview
5.3.3.3 Recent Developments and Future outlook
5.3.4 NBE Therapeutics
5.3.4.1 Company Overview
5.3.4.2 Technology Overview
5.3.4.3 Recent Developments and Future outlook
6. PARTNERSHIPS AND COLLABORATIONS
6.1 Chapter Overview
6.2 Partnership Models
6.3 List of Partnerships and Collaborations
6.3.1 Analysis by Year of Partnership
6.3.2 Analysis by Type of Partnership
6.3.3 Analysis by Type of Linker
6.3.4 Analysis by Type of Conjugation
6.3.5 Analysis by Year of Partnership and Type of Partner
6.3.6 Analysis by Type of Partnership and Type of Partner
6.3.7 Most Active Players: Analysis by Number of Partnerships
6.3.8 Most Popular Technologies: Analysis by Number of Partnerships
6.3.9 Regional Analysis
6.3.10 Intercontinental and Intracontinental Agreements
7. LIKELY PARTNERS ANALYSIS
7.1 Chapter Overview
7.2 Scope and Methodology
7.3 ADC Linker and Conjugation Technologies: Potential Strategic Partners in North America
7.3.1 Most Likely Partners
7.3.2 Likely Partners
7.3.3 Less Likely Partners
7.4 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Europe
7.4.1 Most Likely Partners
7.4.2 Likely Partners
7.4.3 Less Likely Partners
7.5 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Asia-Pacific
7.5.1 Most Likely Partners
7.5.2 Likely Partners
7.5.3 Less Likely Partners
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1 Chapter Overview
8.2 Methodology
8.3 Assumptions and Key Parameters
8.4 Technology Competitiveness Analysis
8.4.1 Technologies Developed by Companies based in North America
8.4.2 Technologies Developed by Companies based in Europe
8.4.3 Technologies Developed by Companies based in Asia Pacific / RoW
9. PATENT ANALYSIS
9.1 Chapter Overview
9.2 Scope and Methodology
9.3 ADC Linker and Conjugation Technologies: Patent Portfolio
9.3.1 Analysis by Publication Year
9.3.2 Analysis by Issuing Authority / Patent Offices Involved
9.3.3 Analysis by CPC Symbols
9.3.4 Emerging Focus Areas
9.3.5 Analysis by Type of Company / Organization
9.3.6 Leading Assignees: Analysis by Number of Patents
9.4 ADC Linker and Conjugation Technologies: Patent Benchmarking Analysis
9.4.1 Analysis by Patent Characteristics
9.5 ADC Linker and Conjugation Technologies: Patent Valuation Analysis
10. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
10.1 Chapter Overview
10.2 First Generation ADC Technologies
10.3 Second Generation ADC Technologies
10.3.1 Cysteine and Selenocysteine Engineering
10.3.2 Unnatural Amino Acid Engineering
10.3.3 Amino-Terminal Serine Engineering
10.4 Third Generation ADC Technologies
10.4.1 Enzyme-Assisted Ligation Approaches
10.4.2 Glycan Remodeling Approaches
10.4.3 Ligation at Fab Nucleotide-Binding Site
10.4.4 Cysteine Rebridging
10.4.5 Avoiding or Limiting Retro-Michael Drug Deconjugation
10.5 Evolutionary Analysis
11. MARKET SIZING AND FORECAST
11.1 Chapter Overview
11.2 Forecast Methodology and Key Assumptions
11.3 Global ADC Linker and Conjugation Technologies Market, 2019-2030
11.4 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030
11.5 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030
11.6 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030
11.7 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030
11.7.1 ADC Linker and Conjugation Technologies Market in North America, 2019-2030
11.7.1.1 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030
11.7.1.2 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030
11.7.1.3 ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030
11.7.2 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030
11.7.2.1 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030
11.7.2.2 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030
11.7.2.3 ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030
11.7.3 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030
11.7.3.1 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030
11.7.3.2 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030
11.7.3.3 ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030
12. EXECUTIVE INSIGHTS
12.1 Chapter Overview
12.2 Miracogen
12.2.1 Company Snapshot
12.2.2 Interview Transcript: Mary Hu, Chief Executive Officer
12.3 NBE Therapeutics
12.3.1 Company Snapshot
12.3.2 Interview Transcript: Wouter Verhoeven, Chief Business Officer
12.4 Synaffix
12.4.1 Company Snapshot
12.4.2 Interview Transcript: Floris van Delft, Chief Scientific Officer
12.5 EUCODIS Bioscience
12.5.1 Company Snapshot
12.5.2 Interview Transcript: Jan Modregger, Head of Research & Development
13. CONCLUDING REMARKS14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List of Figures
Figure 3.1. Components of ADCs
Figure 3.2. Types of Linkers
Figure 4.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Figure 4.2. ADC Linker and Conjugation Technologies: Distribution by ADC Generation
Figure 4.3. ADC Linker and Conjugation Technologies: Distribution by Type of Linker
Figure 4.4. ADC Linker and Conjugation Technologies: Distribution by Type of Conjugation
Figure 4.5. ADC Linker and Conjugation Technologies: Distribution by Site Specificity
Figure 4.6. ADC Linker and Conjugation Technologies: Distribution by Drug to Antibody Ratio
Figure 4.7. ADC Linker and Conjugation Technologies: Distribution by Patent Availability
Figure 4.8. ADC Linker and Conjugation Technologies: Distribution by Licensing Activity
Figure 4.9. ADC Linker and Conjugation Technologies: Distribution by Year of Establishment
Figure 4.10. ADC Linker and Conjugation Technologies: Distribution by Company Size
Figure 4.11. ADC Linker and Conjugation Technologies: Distribution by Geographical Location
Figure 4.12. Leading ADC Developers: Distribution by Number of Technologies
Figure 4.13. Grid Representation: Distribution by ADC Generation, Type of Linker, Company Size, and Geographical Location
Figure 4.14. World Map Representation: Analysis by Geography
Figure 5.1. Catalent Biologics: Annual Revenues, 2014- 2019 (USD Million)
Figure 5.2. Immunomedics: Annual Revenues, 2014-2018 (USD Million)
Figure 5.3. Mersana Therapeutics: Annual Revenues, 2015-2019 (H3) (USD Million)
Figure 5.4. Seattle Genetics: Annual Revenues, 2014-2019 (H1) (USD Million)
Figure 5.5. Sutro Biopharma: Annual Revenues, 2016- 2019 (H3) (USD Million)
Figure 6.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2019
Figure 6.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2014-2019.
Figure 6.4. Partnerships and Collaborations: Distribution by Type of Linker and Type of Partnership
Figure 6.5. Partnerships and Collaborations: Distribution by Type of Conjugation and Type of Partnership
Figure 6.6. Partnerships and Collaborations: Year-wise Trend for Type of Partner
Figure 6.7. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 6.8. Most Active Players: Distribution by Number of Partnerships
Figure 6.9. Most Popular Technologies: Distribution by Number of Partnerships
Figure 6.10. Partnership and Collaborations: Regional Distribution
Figure 6.11. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1. Competitiveness Analysis: Technologies Developed by Companies Based in North America
Figure 8.2. Competitiveness Analysis: Technologies Developed by Companies Based in Europe
Figure 8.3. Competitiveness Analysis: Technologies Developed by Companies Based in Asia Pacific / RoW
Figure 9.1. Patent Analysis: Distribution by Type of Patent
Figure 9.2. Patent Analysis: Cumulative Year-wise Trend, 2016-2019
Figure 9.3. Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 9.4. Patent Analysis: Distribution by CPC Symbols
Figure 9.5. Patent Analysis: Emerging Focus Areas
Figure 9.6. Patent Analysis: Cumulative Distribution by Company / Organization
Figure 9.7. Leading Industry Players in Terms of Number of Patents
Figure 9.8. Leading Non-Industry Players in Terms of Number of Patents
Figure 9.9. Leading Assignees: Distribution by Number of Patents
Figure 9.10. Patent Benchmarking: Roche and AbbVie (based on Patent Characteristics)
Figure 9.11. Patent Benchmarking: Leading Industry Players (based on Patent Characteristics)
Figure 10.1. Evolution of ADC technology Platforms
Figure 10.2. ADC Conjugation Platforms: Technology Landscape
Figure 11.1. Global ADC Linker and Conjugation Technologies Market, 2019-2030 (USD Billion)
Figure 11.2. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.3. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.4. Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030 (USD Billion)
Figure 11.5. Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030 (USD Billion)
Figure 11.6. ADC Linker and Conjugation Technologies Market in North America, 2019-2030 (USD Billion)
Figure 11.7. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.8. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.9. ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030 (USD Billion)
Figure 11.10. ADC Linker and Conjugation Technologies Market in Europe, 2019-2030 (USD Billion)
Figure 11.11. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.12. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.13. ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030 (USD Billion)
Figure 11.14. ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030 (USD Billion)
Figure 11.15. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.16. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.17. ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030 (USD Billion)
List of Tables
Table 3.1. List of Approved Monoclonal Antibody Therapies
Table 3.2. Commonly Used Cytotoxins in ADC Therapeutics
Table 4.1. ADC Linker and Conjugation Technologies: Overall Market Landscape
Table 5.1. Leading ADC Linker and Conjugation Technology Companies
Table 5.2. Ambrx: Company Overview
Table 5.3. Ambrx: Drug Portfolio based on ADC Technology
Table 5.4. Ambrx: Recent Developments and Future Outlook
Table 5.5. Catalent Biologics: Company Overview
Table 5.6. Catalent Biologics: Drug Portfolio based on ADC Technology
Table 5.7. Catalent Biologics: Recent Developments and Future Outlook
Table 5.8. Immunomedics: Company Overview
Table 5.9. Immunomedics: Drug Portfolio based on ADC Technology
Table 5.10. Immunomedics: Recent Developments and Future Outlook
Table 5.11. Mersana Therapeutics: Company Overview
Table 5.12. Mersana Therapeutics: Drug Portfolio based on ADC Technology
Table 5.13. Mersana Therapeutics: Recent Developments and Future Outlook
Table 5.14. Seattle Genetics: Company Overview
Table 5.15. Seattle Genetics: Drugs Drug Portfolio based on ADC Technology
Table 5.16. Seattle Genetics: Recent Developments and Future Outlook
Table 5.17. Sutro Biopharma: Company Overview
Table 5.18. Sutro Biopharma: Drug Portfolio based on ADC Technology
Table 5.19. Sutro Biopharma: Recent Developments and Future Outlook
Table 5.20. Iksuda Therapeutics: Company Overview
Table 5.21. Iksuda Therapeutics: Drug Portfolio based on ADC Technology
Table 5.22. Iksuda Therapeutics: Recent Developments and Future Outlook
Table 5.23. LegoChem Biosciences: Company Overview
Table 5.24. LegoChem Biosciences: Drug Portfolio based on ADC Technology
Table 5.25. LegoChem Biosciences: Recent Developments and Future Outlook
Table 5.26. LinXis: Company Overview
Table 5.27. LinXis: Drug Portfolio based on ADC Technology
Table 5.28. LinXis: Recent Developments and Future Outlook
Table 5.29. NBE Therapeutics: Company Overview
Table 5.30. NBE Therapeutics: Drug Portfolio based on ADC Technology
Table 5.31. NBE Therapeutics: Recent Developments and Future Outlook
Table 6.1. ADC Linker and Conjugation Technologies: Partnerships and Collaborations, 2014-2019
Table 7.1. North America: Most Likely Partners
Table 7.2. North America: Likely Partners
Table 7.3. North America: Less Likely Partners
Table 7.4. Europe: Most Likely Partners
Table 7.5. Europe: Likely Partners
Table 7.6. Europe: Less Likely Partners
Table 7.7. Asia-Pacific: Most Likely Partners
Table 7.8. Asia-Pacific: Likely Partners
Table 7.9. Asia-Pacific: Less Likely Partners
Table 9.1. Patent Analysis: CPC Symbol Definitions
Table 9.2. Patent Analysis: Popular CPC Symbols
Table 9.3. Patent Analysis: List of Top CPC Symbols
Table 9.4. Patent Analysis: List of Leading Assignees
Table 9.5. Patent Analysis: Benchmarking Analysis Summary
Table 9.6. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 10.1. Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 10.2. Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 10.3. Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 10.4. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 10.5. Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 10.6. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 10.7. Third Generation ADC Technologies: Cysteine Rebridging
Table 10.8. Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 12.1. Miracogen: Key Highlights
Table 12.2. NBE Therapeutics: Key Highlights
Table 12.3. Synaffix: Key Highlights
Table 12.4. EUCODIS Bioscience: Key Highlights
Table 14.1 ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Table 14.2 ADC Linker and Conjugation Technologies: Distribution by ADC Generation
Table 14.3 ADC Linker and Conjugation Technologies: Distribution by Type of Linker
Table 14.4 ADC Linker and Conjugation Technologies: Distribution by Type of Conjugation
Table 14.5 ADC Linker and Conjugation Technologies: Distribution by Site Specificity
Table 14.6 ADC Linker and Conjugation Technologies: Distribution by Drug to Antibody Ratio
Table 14.7 ADC Linker and Conjugation Technologies: Distribution by Patent Availability
Table 14.8 ADC Linker and Conjugation Technologies: Distribution by Licensing Activity
Table 14.9 ADC Linker and Conjugation Technologies: Distribution by Year of Establishment
Table 14.10 ADC Linker and Conjugation Technologies: Distribution by Company Size
Table 14.11 ADC Linker and Conjugation Technologies: Distribution by Geographical Location
Table 14.12 Leading ADC Developers: Distribution by Number of Technologies
Table 14.13 Catalent Biologics: Annual Revenues, 2014- 2019 (USD Million)
Table 14.14 Immunomedics: Annual Revenues, 2014-2018 (USD Million)
Table 14.15 Mersana Therapeutics: Annual Revenues, 2015-2019 (H3) (USD Million)
Table 14.16 Seattle Genetics: Annual Revenues, 2014-2019 (H1) (USD Million)
Table 14.17 Sutro Biopharma: Annual Revenues, 2016- 2019 (H3) (USD Million)
Table 14.18 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2019
Table 14.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.20 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 14.21 Partnerships and Collaborations: Distribution by Type of Linker and Type of Partnership
Table 14.22 Partnerships and Collaborations: Distribution by Type of Conjugation and Type of Partnership
Table 14.23 Partnerships and Collaborations: Year-wise Trend for Type of Partner
Table 14.24 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.25 Most Active Players: Distribution by Number of Partnerships
Table 14.26 Most Popular Technologies: Distribution by Number of Partnerships
Table 14.27 Partnership and Collaborations: Regional Distribution
Table 14.28 Patent Analysis: Distribution by Type of Patent
Table 14.29 Patent Analysis: Cumulative Year-wise Trend, 2016-2019
Table 14.30 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Table 14.31 Patent Analysis: Distribution by CPC Symbols
Table 14.32 Patent Analysis: Emerging Focus Areas
Table 14.33 Patent Analysis: Cumulative Distribution by Company / Organization
Table 14.34 Leading Industry Players in Terms of Number of Patents
Table 14.35 Leading Non-Industry Players in Terms of Number of Patents
Table 14.36 Leading Assignees: Distribution by Number of Patents
Table 14.37 Global ADC Linker and Conjugation Technologies Market, 2019-2030 (USD Billion)
Table 14.38 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.39 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.40 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030 (USD Billion)
Table 14.41 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030 (USD Billion)
Table 14.42 ADC Linker and Conjugation Technologies Market in North America, 2019-2030 (USD Billion)
Table 14.43 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.44 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.45 ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030 (USD Billion)
Table 14.46 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030 (USD Billion)
Table 14.47 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.48 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.49 ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030 (USD Billion)
Table 14.50 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030 (USD Billion)
Table 14.51 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.52 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.53 ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030 (USD Billion)

Companies Mentioned

  • 3P Biopharmaceuticals
  • 3SBio
  • AbbVie
  • AbGenomics
  • ABL Bio
  • Abnova
  • Abzena
  • ACES Pharma
  • ADC Biotechnology
  • ADC Therapeutics
  • Advanced Proteome Therapeutics
  • Affinity Life Sciences
  • AGC Biologics
  • Agensys
  • Ajinomoto
  • Ajinomoto Bio-Pharma Services
  • Albumedix
  • Alexion Pharmaceuticals
  • Allergan
  • Alpha Cancer Technologies
  • Alta Partners
  • Alteogen
  • Ambrx
  • Amgen
  • Angiex
  • Antikor Biopharma
  • Araris Biotech
  • Asana BioSciences
  • Astellas Pharma
  • AstraZeneca
  • Avacta Life Sciences
  • Bayer
  • BeiGene
  • BioAtla
  • BioCapital
  • Biogen
  • BioLegend
  • BioMed Valley Discoveries
  • BioOutsource
  • Bio-Rad Laboratories
  • Bio-Synthesis
  • Biotechnique
  • Biotest
  • Bio-Thera Solutions
  • BlinkBio
  • Bliss Biopharmaceutical
  • BOC Sciences
  • Boehringer Ingelheim
  • Boster Biological Technology
  • Bristol-Myers Squibb
  • BSP Pharmaceuticals
  • Cancer Research UK
  • Capra Science Antibodies
  • CARBOGEN AMCIS
  • Cascadian Therapeutics
  • Catalent Biologics
  • Celgene
  • CellMosaic
  • Cell Signalling Technology
  • Cellerant Therapeutics
  • Celltrion
  • Centrose
  • Cerbios-Pharma
  • Chugai Pharmaceutical
  • Cisbio
  • Clovis Oncology
  • Concortis Biotherapeutics
  • Corixa
  • Creative Biolabs
  • Creative Diagonostics
  • Creative peptides
  • CSPC Pharmaceutical Group
  • CureMeta
  • Cytogen
  • CytomX Therapeutics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Debiopharm Group
  • Dyax
  • Eisai
  • Elan Pharmaceuticals
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Envigo
  • Esperance Pharmaceuticals
  • EUCODIS Bioscience
  • Eventide Asset Management
  • Everest Biotech
  • Everest Medicines
  • Exelixis
  • Expedeon
  • Femtogenix
  • Fleet Bioprocessing
  • Formation Biologics
  • Formosa Laboratories
  • Fortis Therapeutics
  • Fosun Pharma
  • GamaMabs Pharma
  • Genentech
  • Genmab
  • Genovis
  • GenScript
  • Genzyme
  • GlaxoSmithKline
  • Glycotope
  • Glythera
  • Goodwin Biotechnology
  • GT Biopharma
  • Hangzhou DAC Biotech
  • Heidelberg Pharma
  • Hengrui Medicine
  • Human Genome Sciences
  • iBioSource
  • Iconic Therapeutics
  • Iksuda Therapeutics
  • ImClone Systems
  • ImmunoBiochem
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • Innovate UK
  • IntoCell
  • IONTAS
  • iProgen Biotech
  • Iterum Therapeutics
  • Janssen Biotech
  • Johnson & Johnson
  • Johnson Matthey
  • Kairos Therapeutics
  • KLUS Pharma
  • Kyowa Hakko Kirin
  • LakePharma
  • LegoChem Bioscienses
  • Leinco Technologies
  • Leukemia & Lymphoma Society
  • Levena Biopharma
  • Life Technologies
  • Light Chain Bioscience
  • Lilly Ventures
  • LinXis
  • MabPlex
  • MabSpace Biosciences
  • MabVax Therapeutics
  • MacroGenics
  • Magenta Therapeutics
  • Maine Biotechnology
  • MediaPharma
  • MedImmune
  • Meditope Biosciences
  • MedKoo Biosciences
  • Memorial Sloan Kettering Cancer Center
  • Menarini Group
  • Merck
  • Mersana Therapeutics
  • Millennium Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • Morphotek
  • MuseChem
  • NanoValent Pharmaceuticals
  • National Research Council of Canada
  • NBE-Therapeutics
  • NeoRx
  • Nexthera Capital
  • Nordic Nanovector
  • Noria Pharmaceuticals
  • Novartis
  • NovaTeinBio Novimmune
  • NovoCodex Biopharmaceuticals
  • Novozymes
  • OBI Pharma
  • OcellO
  • OGD2 Pharma
  • Oncolinx
  • Oncomatryx Biopharma
  • Oncotec Pharma Produktion
  • Organon Teknika
  • OriGene Technologies
  • Oxford BioTherapeutics
  • Palatin Technologies
  • Pfizer
  • Pharmaron
  • Philochem
  • Pierre Fabre
  • Piramal Pharma Solutions
  • ProBioGen
  • Progenics Pharmaceuticals
  • ProteoGenix
  • Puma Biotechnology
  • Rakuten Medical
  • Recepta Biopharma
  • Redwood Bioscience
  • Regeneron Pharmaceuticals
  • RemeGen
  • Roche
  • Rockland Immunochemicals
  • SafeBridge Consultants
  • Samsung Medical Center
  • Sanofi
  • Seattle Genetics
  • Seramun Diagnostica
  • Servier
  • Sesen Bio
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Shanghai Jiaolian Medicine Research and Development
  • Shanghai Miracogen
  • Shenogen Pharma
  • Shire
  • Siamab Therapeutics
  • Skyline Ventures
  • Sorrento Therapeutics
  • SOTIO
  • SouthernBiotech
  • Sun Pharmaceutical Industries
  • Sunomix Biosciences
  • Surveyor Capital
  • Sutro Biopharma
  • SV Health Investors
  • Swedish Orphan Biovitrum (Sobi)
  • Synaffix
  • Syngene International
  • Synthon
  • TaiMed Biologics
  • Takeda Pharmaceutical
  • TBD-Biodiscovery
  • Teresi Pharmaceuticals
  • Teva Pharmaceutical
  • The Johns Hopkins University School of Medicine
  • The University of Texas MD Anderson Cancer Center
  • Theratechnologies
  • Thermo Fisher Scientific
  • ThioLogics
  • TOT BIOPHARM
  • Triphase Accelerator
  • Tsuchikama Laboratory
  • UCB
  • Ultragenyx Pharmaceutical
  • United Therapeutics
  • UW Carbone Cancer Center
  • Vaccinex
  • Valeant Pharmaceuticals
  • VelosBio
  • Vida Ventures
  • Visterra
  • WuXi Biologics
  • Wyeth
  • Xintela
  • Yale Cancer Center
  • Y-Biologics
  • Zhejiang Hisun Pharmaceutical
  • Zymeworks

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035 - Product Image

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 716 Pages
  • Global
From
Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028 - Product Image

Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028

  • Report
  • 55 Pages
  • Global
From
Antibody Drug Conjugates Global Market Report 2024 - Product Image

Antibody Drug Conjugates Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 184 Pages
  • Global
From
Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028 - Product Image

Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

  • Report
  • 273 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.